Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Plans Likely To Focus On Managing Use Of Low-Cost Drugs

Executive Summary

The catastrophic coverage provided under the Medicare Part D benefit may give private plan sponsors little incentive to control use of high-cost drugs, American Enterprise Institute Resident Fellow Scott Gottlieb said April 27

You may also be interested in...



Enbrel To Cut Into Remicade’s Medicare Monopoly Via Part D, Amgen Says

Amgen sees the advent of Part D as an opportunity for Enbrel to capture some of the Medicare TNF inhibitor rheumatoid arthritis market share currently held byJohnson & Johnson's Remicade

Enbrel To Cut Into Remicade’s Medicare Monopoly Via Part D, Amgen Says

Amgen sees the advent of Part D as an opportunity for Enbrel to capture some of the Medicare TNF inhibitor rheumatoid arthritis market share currently held byJohnson & Johnson's Remicade

Biologics Under Part D: Coinsurance, Cost Containment And Coverage Overlap

Coinsurance appears to be the preferred cost-sharing method for biologics in Medicare Part D plans, according to an analysis of plan formularies by "The Pink Sheet."

Related Content

Topics

UsernamePublicRestriction

Register

PS045751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel